SandboxAQ’s Luca Ferrara discusses the rising risk of GPS jamming and spoofing, and how aviation is seeking new ways to stay ...

Vor Bio is the latest cell therapy company to reach the end of the road. The biotech is immediately winding down clinical and manufacturing operations and laying off almost all staff. Around 95% of ...

Running two days late, SpaceX launched its huge Super Heavy-Starship on Tuesday, chalking up what appeared to be a remarkably successful test flight in the wake of three back-to-back failures earlier ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune asset ...